Other · developed by Spyre Therapeutics
SPY002 is a drug name with no further detail in the available sources. It is studied in ulcerative colitis, an inflammatory bowel disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07012395 | Phase 2 | Ulcerative Colitis | Recruiting | SYRE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ColitisColitis, UlcerativeInflammatory Bowel DiseasesUlcerative Colitis
See SYRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SYRE catalysts and pipeline →